Flavoxate

CHEMBL1493 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
391.5 g/mol
LogP
4.3
Phase
4

This medication relaxes the smooth muscle of the bladder to relieve urinary urgency, frequency, and pain associated with various urinary tract conditions. It works by blocking calcium channels and has mild anticholinergic and analgesic properties.

الوزن الجزيئي

391,5000 g/mol

LogP

4,30

TPSA

55,80 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

آلية العمل

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O

InChI

InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3

Molecular Formula

C24H25NO4

HBD / HBA

- / 5

الروابط القابلة للدوران

6

الذرات الثقيلة

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This medication relaxes the smooth muscle of the bladder to relieve urinary urgency, frequency, and pain associated with various urinary tract conditions. It works by blocking calcium channels and has mild anticholinergic and analgesic properties.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Flavoxate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1493. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3354. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.